Trial Profile
Efficacy and QOL of switching from insulin glargine U100 or insulin deglidec to insulin glargine U300 in type2 diabetes mellitus
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2022
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 04 Aug 2022 Status changed from active, no longer recruiting to discontinued.
- 02 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2018 New trial record